MDMA, also known as ecstasy, is being studied as a treatment for PTSD and anxiety, with approval expected soon. Although MDMA affects serotonin and could theoretically cause serotonin syndrome—a potentially dangerous condition—no cases have occurred in clinical trials. A review of FDA adverse event reports found 20 cases of serotonin syndrome in people who took MDMA, but all had also used other serotonergic drugs such as amphetamines, stimulants, or opioids. No cases were linked to MDMA alone. These findings suggest that serotonin syndrome from MDMA alone is rare or absent in the available data.
MDMA is being tested as a treatment aid for PTSD and anxiety disorders, and regulatory approval is expected soon. Its main effects involve increasing serotonin, norepinephrine, and dopamine activity, which can raise heart rate and blood pressure. Clinical trials have limited data on cardiac side effects due to small participant numbers and restricted use of other drugs. An analysis of FDA adverse event reports found 17 cardiovascular cases where people took MDMA plus other substances. All accompanying drugs—opioids, stimulants, anticholinergics, and amphetamines—are already linked to heart problems. In none of these reports was MDMA considered the primary cause.